{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:01:26Z","timestamp":1783796486176,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.schres.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T03:15:37Z","timestamp":1493176537000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder"],"prefix":"10.1016","volume":"192","author":[{"given":"Dong-Jing","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-2086","authenticated-orcid":false,"given":"David","family":"Walling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina R.","family":"Schooler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-6905","authenticated-orcid":false,"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.schres.2017.04.004_bb0005","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/14656566.2016.1161029","article-title":"Paliperidone for the treatment of schizoaffective disorder","volume":"17","author":"Alphs","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2017.04.004_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.schres.2017.04.004_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/NDT.S15911","article-title":"Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America","volume":"7","author":"Apiquian","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.04.004_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2011.08.024","article-title":"Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder","volume":"133","author":"Boden","year":"2011","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2017.04.004_bb0025","first-page":"403","article-title":"Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr","volume":"116","author":"Burns","year":"2007","journal-title":"Scandinavica"},{"key":"10.1016\/j.schres.2017.04.004_bb0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/NDT.S12612","article-title":"Role of paliperidone extended-release in treatment of schizoaffective disorder","volume":"6","author":"Canuso","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.schres.2017.04.004_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/17512433.2016.1121809","article-title":"Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil","volume":"9","author":"Citrome","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2017.04.004_bb0040","series-title":"Analysis of Longitudinal Data","author":"Diggle","year":"2002"},{"issue":"1","key":"10.1016\/j.schres.2017.04.004_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","article-title":"Pharmacologic treatment of hospitalized patients with schizoaffective disorder","volume":"53","author":"Flynn","year":"2002","journal-title":"Psychiatr. Serv."},{"issue":"3","key":"10.1016\/j.schres.2017.04.004_bb0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2017.04.004_bb0055","series-title":"Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]","author":"Janssen Pharmaceuticals, Inc.","year":"2014"},{"issue":"3","key":"10.1016\/j.schres.2017.04.004_bb0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40258-014-0095-8","article-title":"Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder","volume":"12","author":"Karve","year":"2014","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"1","key":"10.1016\/j.schres.2017.04.004_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pnpbp.2003.09.024","article-title":"Combination of \u201catypical\u201d antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder","volume":"28","author":"Lerner","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.04.004_bb0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-016-0551-x","article-title":"Antipsychotic management of schizoaffective disorder: a review","volume":"76","author":"Lindenmayer","year":"2016","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.schres.2017.04.004_bb0075","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.04.004_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2013.04.026","article-title":"Schizoaffective disorder in the DSM-5","volume":"150","author":"Malaspina","year":"2013","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.04.004_bb0085","first-page":"352","article-title":"Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr","volume":"82","author":"Marneros","year":"1990","journal-title":"Scand."},{"issue":"6","key":"10.1016\/j.schres.2017.04.004_bb0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/YIC.0000000000000038","article-title":"Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study","volume":"29","author":"McDonnell","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl. 5","key":"10.1016\/j.schres.2017.04.004_bb0095","first-page":"16","article-title":"An overview of the treatment of schizoaffective disorder","volume":"60","author":"McElroy","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.04.004_bb0100","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"4 suppl 1","key":"10.1016\/j.schres.2017.04.004_bb0105","first-page":"S1","article-title":"Differential diagnosis and therapeutic management of schizoaffective disorder","volume":"22","author":"Nasrallah","year":"2010","journal-title":"Ann. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.04.004_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","article-title":"Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia","volume":"161","author":"Nasrallah","year":"2008","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.schres.2017.04.004_bb0115","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1185\/03007991003798927","article-title":"Personal and social function in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention","volume":"26","author":"Nicholl","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.schres.2017.04.004_bb0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.04.004_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2017.04.004_bb0130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","article-title":"Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia","volume":"30","author":"Parellada","year":"2016","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2017.04.004_bb0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14656566.2015.1114100","article-title":"Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia","volume":"17","author":"Potkin","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2017.04.004_bb0140","series-title":"Linear Mixed Models for Longitudinal Data","author":"Verbeke","year":"2000"},{"key":"10.1016\/j.schres.2017.04.004_bb0145","first-page":"417","article-title":"Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada","volume":"10","author":"Williams","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:27:36Z","timestamp":1760297256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417301913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":29,"alternative-id":["S0920996417301913"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.04.004","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}